Comparing Innovation Spending: AbbVie Inc. and Soleno Therapeutics, Inc.

Innovation Spending: A Tale of Two Companies

In the ever-evolving landscape of pharmaceuticals, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, AbbVie Inc. and Soleno Therapeutics, Inc. have demonstrated contrasting approaches to R&D investment.

AbbVie Inc.: A Giant in Innovation

Since 2014, AbbVie has consistently invested heavily in R&D, with expenditures peaking at approximately $10 billion in 2018. This represents a staggering 200% increase from their 2014 spending. Such robust investment underscores AbbVie's dedication to maintaining its competitive edge in the pharmaceutical industry.

Soleno Therapeutics, Inc.: A Nimble Innovator

In contrast, Soleno Therapeutics, a smaller player, has shown a steady increase in R&D spending, reaching around $25 million in 2023. While their absolute numbers are modest compared to AbbVie, Soleno's R&D expenses have grown by over 1000% since 2014, highlighting their agile approach to innovation.